Literature DB >> 4545894

Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses.

M B Pepys.   

Abstract

In an in vivo study in mice, suppression by the C3-cleaving protein of cobra venom (CoF), and other C3-reactive agents (zymosan, aggregated IgG, anti-C3 antibodies, and type III pneumococcal polysaccharide) of the thymus-dependent antibody responses to sheep erythrocytes, ovalbumin, and human IgG was demonstrated. The thymus-independent antibody response to polyvinyl-pyrrolidone was however unaffected by CoF. These and other published observations suggest that there may be a requirement for functional C3 in induction of thymus-dependent but not thymus-independent antibody production. A model for the role of C3 in lymphocyte cooperation is proposed based on these data analyzed in the light of existing knowledge of this process. It is postulated that fixed C3 interacting with macrophage See PDF for Structure and B-cell C3 receptors might enhance or facilitate T-dependent presentation of antigen to B cells.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4545894      PMCID: PMC2139695          DOI: 10.1084/jem.140.1.126

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  Passive sensitization of lymphocytes and macrophages by antigen-antibody complexes.

Authors:  J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1965-12       Impact factor: 11.205

2.  The adherence of leucocytes and platelets induced by fixed IgG antibody or complement.

Authors:  P M Henson
Journal:  Immunology       Date:  1969-01       Impact factor: 7.397

3.  Induction of immunity and immunologic paralysis in mice against polyvinyl pyrrolidone.

Authors:  B Andersson
Journal:  J Immunol       Date:  1969-05       Impact factor: 5.422

4.  Thymus dependence of antibody response: variation with dose of antigen and class of antibody.

Authors:  R B Taylor; H H Wortis
Journal:  Nature       Date:  1968-11-30       Impact factor: 49.962

5.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  Studies on actively allergized cells. I. The cyto-dynamics and morphology of rosete-forming lymph node cells in mice and inhibition of rosette-formation with antibody to mouse immunoglobulins.

Authors:  I McConnell; A Munro; B W Gurner; R R Coombs
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

8.  Competition of 19S and 7S antigen receptors in the regulation of the primary immune response.

Authors:  C Henry; N K Jerne
Journal:  J Exp Med       Date:  1968-07-01       Impact factor: 14.307

9.  Cell interactions in the primary immune response in vitro: a requirement for specific cell clusters.

Authors:  D E Mosier
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  86 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Homozygous hereditary C3 deficiency due to a premature stop codon.

Authors:  Edimara Da Silva Reis; Gisele Vanessa Baracho; Adriana Sousa Lima; Chuck S Farah; Lourdes Isaac
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

3.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 4.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 5.  The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens.

Authors:  A Zandvoort; W Timens
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

6.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

Authors:  Rangaiah Shashidharamurthy; Randolph A Hennigar; Sebastien Fuchs; Purani Palaniswami; Melanie Sherman; Periasamy Selvaraj
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

8.  Inherited deficiency of the second component of complement. Rheumatic disease associations.

Authors:  D Glass; D Raum; D Gibson; J S Stillman; P H Schur
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

9.  The anti-lipid A antibody HA-1A binds to rough gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35).

Authors:  M Tonoli; K A Davies; P J Norsworthy; J Cohen; M J Walport
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.